BioPharma Dive December 5, 2022
Sponsored content By Syneos Health

To better understand how medications impact the people who use them, participants in clinical trials should reflect real-life demographics. And yet, a U.S. Food and Drug Administration (FDA) analysis of clinical trials in 2020 found participants were largely homogenous and unrepresentative of the populations the healthcare industry serves: globally, 76% of enrolled participants were white, while just 11% were Asian and 7% were Black.1 In the United States, 78% of enrolled participants were white while roughly 22% were people of color,1 despite having a population nearly twice that number.2

These disparities could potentially hinder healthcare, says Angel Akinbinu, who is director for site and patient diversity with Syneos Health®. “When we do not have diversity in our trials, we run...

Today's Sponsors


Today's Sponsor

Health Edge

Topics: Biotechnology, Clinical Trials, Equity/SDOH, FDA, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Trends
Three Wild Health Technologies in (or Close to) Clinical Trials
How the Cloud Can Improve Data Sets for Real-World Evidence in Clinical Trials
Health Equity Barriers in Oncology Trials
Nationwide Children's Hospital AI spinoff acquired by new $200M clinical trial startup
Clinical trial company Science 37 buys life science assets from Vault Health

Share This Article